Registered Nurse in Elgin, ND Accepting Medicare
2 Registered Nurse nurses found. Showing 1 - 2
 Maria Aune, FNP-C Registered Nurse Medicare: Medicare Enrolled Practice Location: 601 East St N, Elgin, ND 58533 Phone: 701-584-2792 |
Mrs. Avery Dawn Henke, FNP-BC Registered Nurse Medicare: Medicare Enrolled Practice Location: 601 East St N, Elgin, ND 58533 Phone: 701-584-2792 |
News Archive
ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys
A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.
American Academy of Dermatology releases final guidelines of care for psoriasis
Building on the evidence-based findings of five previously published guidelines of care that examine the use of a variety of medical therapies for the management and treatment of psoriasis and psoriatic arthritis, the American Academy of Dermatology has released its sixth and final guidelines of care for psoriasis.
Researchers identify new molecular pathway involved in alveoli growth
In a study of mice, researchers at Johns Hopkins have identified a new molecular pathway involved in the growth of tiny air sacs called alveoli that are crucial for breathing. The scientists say their experiments may lead to the first successful treatments to regrow the air sacs in people who suffer from diseases such as emphysema in which the air sacs have been destroyed by years of smoking.
MHRA issues notice of acceptance for BioMarin's GALNS Phase 3 trial in MPS IVA
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
› Verified 4 days ago